ProMIS Neurosciences Files 2025 Proxy Statement

TL;DR

ProMIS Neurosciences proxy filed - vote on board, pay, and strategy for June 12 meeting.

AI Summary

ProMIS Neurosciences Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 12, 2025. The company, formerly known as Amorfix Life Sciences Ltd., is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other shareholder proposals.

Why It Matters

This filing provides shareholders with crucial information to make informed decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: medium — Proxy statements can signal upcoming strategic shifts or governance changes that may impact stock price.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• Amorfix Life Sciences Ltd. (company) — Former company name
• June 12, 2025 (date) — Annual meeting date
• April 29, 2025 (date) — Filing date

FAQ

From the Filing

0001558370-25-005871.txt : 20250429 0001558370-25-005871.hdr.sgml : 20250429 20250429171427 ACCESSION NUMBER: 0001558370-25-005871 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250612 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 25889441 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 DEF 14A 1 pmn-20250612xdef14a.htm DEF 14A PROMIS NEUROSCIENCES INC. DEF 14A 0001374339 false 0001374339 2024-01-01 2024-12-31 Table of Contents ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No.  ) ​ Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 PROMIS NEUROSCIENCES INC. (Name of Registrant as Specified in its Charter) Not applicable. (Name of Person (s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11. ​ ​ ​ ​ Table of Contents PROMIS NEUROSCIENCES INC. SUITE 200, 1920 YONGE STREET TORONTO, ONTARIO, CANADA M4S 3E2 (416) 847-6898 NOTICE OF 2025 ANNUAL MEETING OF SHAREHOLDERS To Be Held on June 12, 2025 To Our Shareholders: You are cordially invited to attend the 2025 Annual Meeting of Shareholders of ProMIS Neurosciences Inc. (the “Annual Meeting”). This year’s Annual Meeting will be a virtual meeting, which will be conducted via live webcast on Thursday, June 12, 2025 at 10:00 a.m., Eastern Time. You may attend the meeting virtually by registering at http://www.virtualshareholdermeeting.com/PMN2025 , where you will be able to vote electronically and submit questions, subject to the registration procedures set forth below. Only shareholders who owned common shares at the close of business on April 16, 2025 can vote at the Annual Meeting or any adjournment that may take place. At the Annual Meeting, the shareholders will consider and vote on the following matters: 1. To elect seven directors, each to serve until the next annual meeting of shareholders and until his or her respective successors is duly elected and qualified, or such director’s earlier death, resignation, or removal; 2. To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 3. To approve the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan; and 4. To transact any other business that may properly come before the Annual Meeting or any adjournment thereof. In addition, at our Annual Meeting, the shareholders will receive (but not vote on) the consolidated financial statements of the Company for the fiscal year ended December 31, 2024, includin